# An online tool for correcting verification bias when validating electronic phenotyping algorithms.

- Ajay Bhasin, MD<sup>1,2</sup>; Suzette J. Bielinski, PhD, MEd<sup>3</sup> Abel N. Kho, MD<sup>4,5</sup>; Nicholas B. Larson
- 4 PhD, MS<sup>\*6</sup>; Laura Rasmussen-Torvik, MPH, PhD<sup>\*7</sup>
- <sup>1</sup>Department of Medicine, Division of Hospital Medicine, Northwestern University Feinberg
- 6 School of Medicine, Chicago, IL
- 7 <sup>2</sup>Department of Pediatrics, Division of Hospital-Based Medicine, Northwestern University
- 8 Feinberg School of Medicine, Chicago, IL
- <sup>3</sup>Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic College of
   Medicine and Science, Rochester, Minnesota, USA
- <sup>4</sup>Center for Health Information Partnerships, Institute for Public Health & Medicine, Feinberg
- 12 School of Medicine, Northwestern University, Chicago, IL, USA.
- <sup>5</sup>Division of General Internal Medicine, Department of Medicine, Feinberg School of Medicine,
- 14 Northwestern University, Chicago, IL, USA.
- <sup>6</sup>Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo
- 16 Clinic College of Medicine and Science, Rochester, MN, USA
- <sup>17</sup> <sup>7</sup>Department of Preventive Medicine, Division of Epidemiology, Northwestern University
- 18 Feinberg School of Medicine
- 19 \*These authors contributed equally
- 20 Abstract word Count: 153
- 21 Word count: 1293
- 22 **Tables**: 2
- 23 Conflict of Interest Disclosures: To the best of our knowledge, no conflict of interest, financial
- or other, exists with respect to the information provided in this report.
- 25 **Funding/Support**: None.

# 26 Address for Correspondence:

- 27 Ajay Bhasin, MD; Assistant Professor; Department of Medicine and Department of Pediatrics;
- 28 Northwestern University Feinberg School of Medicine
- 29 Address: 257 E Huron, Suite 16-738, Chicago, IL 60611
- 30 Email: <u>ajay.bhasin@nm.org</u>
- 31 ORCiD: 0000-0001-5577-2065 | Twitter: @Ajaybhasin19 | Phone: (312) 926-5893

# 32 Abstract

Computable or electronic phenotypes of patient conditions are becoming more commonplace in 33 quality improvement and clinical research. During phenotyping algorithm validation, standard 34 classification performance measures (i.e., sensitivity, specificity, positive predictive value, 35 negative predictive value, and accuracy) are commonly employed. When validation is 36 37 performed on a randomly sampled patient population, direct estimates of these measures are 38 valid. However, it is common that studies will sample patients conditional on the algorithm result, leading to a form of bias known as verification bias. The presence of verification bias 39 requires adjustment of performance measure estimates to account for this sampling bias. Herein, 40 41 we describe the appropriate formulae for valid estimates of sensitivity, specificity, and accuracy 42 to account for verification bias. We additionally present an online tool to adjust algorithm performance measures for verification bias by directly taking the sampling strategy into 43 consideration and recommend use of this tool to properly estimate algorithm performance for 44 phenotyping validation studies. 45

## 46 Introduction

Computable phenotypes of patient conditions are becoming more commonplace in quality 47 improvement and clinical research.<sup>1</sup> These phenotypes are algorithmically derived from data 48 sources such as electronic health record (EHR), insurance claims, or centers for Medicare and 49 Medicaid Services data, and can empower research and improve patient care.<sup>2,3</sup> Algorithm 50 performance measures, such as sensitivity, specificity, and positive and negative predictive 51 52 values (PPV and NPV) are common measures of validity obtained by comparing the algorithm 53 result to a "gold standard" (e.g. manual chart review). A common validation study design strategy when the condition of interest has low prevalence is to sample based on the algorithm 54 result (e.g. 50 predicted cases and 50 predicted non-cases).<sup>4,5</sup> This strategy is both cost-effective 55 and statistically efficient by enriching for likely true positives and improving the expected 56 precision of positive-class performance measures (e.g., sensitivity, PPV). However, this 57 sampling strategy also results in a form of selection bias known as verification bias, which is 58 commonly encountered in diagnostic test evaluation.<sup>6-8</sup> Under these conditions, estimates of 59 sensitivity, specificity, and accuracy can be biased if the sampling design is not taken into 60 consideration. Herein, we illustrate the effects of verification bias on performance estimation 61 through an example validation study and develop a user-friendly online tool to facilitate 62 63 adjustment of performance measures under these validation study scenarios.

64 Methods

Given that EHR-based phenotyping algorithms can be prone to error, it is often of interest to
characterize classification performance relative to ground truth based on manual chart
abstraction. Formulae for defining these performance measures adjusting estimates of sensitivity
and specificity for verification bias are available in Figure 1. Detailed explanations of these

derivations, along with formulae for calculating corresponding asymptotic CI's, are provided by Begg and
 Greenes.<sup>9</sup>

71

## 72 Validation Study Sampling Design

For phenotyping algorithms, the total number of patients with available classification results 73 74 tends to be very large due to ease of implementation (e.g., the entire patient population at a medical institution). Given the potential laborious nature of chart review, algorithm validation 75 studies are often performed on a relatively small subset of the total population. When the 76 77 expected prevalence of the disease condition is low (i.e., less than 10%), validation studies may have correspondingly low precision for estimating sensitivity and PPV if patients are randomly 78 79 sampled from the population. For example, for a disease with prevalence of 2%, in a random 80 sample of 500 patients we expect 10 positive disease patients, on average. Even at a true algorithm sensitivity of 90% (i.e., 9/10 cases correctly identified), the Wilson score 95% 81 confidence interval (CI) would be [0.596,0.995]. In contrast, 90% specificity would correspond 82 to a 95% confidence interval of [0.870,0.925]. This disparity in precision can be mitigated by 83 oversampling subjects predicted by the algorithm as a positive case (e.g., 1:1 sampling based on 84 85 predicted disease status), leading to a more balanced representation of true disease cases and unaffected non-cases within the validation sample. 86

## 87 Naïve and Adjusted Validation Performance

While the sampling strategy defined above leads to more statistically efficient estimation of
algorithm performance, sampling patients for the validation study based on algorithm-classified
disease status can lead to biased estimation of performance measures. Referred to as

91	"verification" or "work-up" bias, unadjusted analyses of the resulting validation 2x2 contingency
92	table can specifically lead to overestimated sensitivity while simultaneously underestimating
93	specificity. However, since NPV and PPV correspond to probabilities conditional on predicted
94	statuses, these estimates remain valid under this conditional sampling scheme.
95	Example Validation Study
96	Consider the illustrative example of a validation study where a phenotyping algorithm is
97	applied to a source population of 1,100 patients, corresponding to 100 patients classified as
98	positive and 1000 patients as negative. From this cohort, 50 predicted cases and 50 predicted
99	non-cases were selected for phenotyping algorithm validation. The manual abstraction yielded a
100	2x2 contingency table with counts of 49 true positives, 1 false positive, 3 false negatives, and 47
101	true negatives.

### 102 Simulation Analysis

103 To further illustrate the impact of verification bias on sensitivity and specificity estimates across 104 a broad range of realistic study conditions, we conducted a simple simulation study for a disease with estimated true prevalence between 1% and 50%; true NPV of 0.90, 0.95, and 0.99; and true 105 PPV of 0.70, 0.80, and 0.90. For validation, we considered a balanced study design, such that 106 equal numbers of predicted cases and non-cases are selected for chart abstraction. We then 107 calculated the expected bias of naive estimates of sensitivity and specificity relative to 108 109 appropriately adjusted estimates based on expected values of true positive rate (TPR), false 110 positive rate (FPR), true negative rate (TNR), and false negative rate (FNR) in the validation study. 111

## 112 Online Tool

113 We used Microsoft Visual Studio Code (version 1.78.0) and Python (version 3.10) with the

114 *Streamlit* package (version 1.13.0) to create a simple tool to calculate sensitivity, specificity,

115 PPV, NPV, and accuracy of a phenotyping algorithm based on chart validation. The tool is

116 freely available at: https://bit.ly/3tMTJiE.

## 117 **Results**

118 The 2x2 contingency table of the example validation study along with projected counts from the total source cohort are presented in Table 1, while respective performance measure analyses 119 corresponding to unadjusted and verification-bias adjusted estimates are presented in Table 2. 120 121 Unadjusted performance estimates for the hypothesized phenotyping algorithm corresponded to 0.942 sensitivity, 0.979 specificity, and 0.960 accuracy. The disease prevalence in the validation 122 study sample was 0.520, whereas the true prevalence in the source population was 0.091. After 123 124 adjusting for verification bias, the updated performance measures for the algorithm corresponded to 0.620 sensitivity, 0.999 specificity, and 0.944 accuracy. 125

126 Results from our simulation study are presented in Figure 2. These results illustrate the 127 substantial positive bias for sensitivity estimation that may be observed as disease prevalence decreases toward zero when analyzing the unadjusted validation study confusion matrix results. 128 129 This bias relationship is attenuated as the NPV approaches 1.00, but still yields extreme bias at lower prevalence values. For specificity (Figure 2B), we observe similar trends of increased 130 absolute bias with decreased prevalence. However, the magnitude of this bias remains largely 131 consistent across realistically high values of NPV considered for the simulation study, with lower 132 PPV leading to moderate increases in bias. Of note, these results represented expected biases, 133 134 and actual results may vary based on sizes of the total population and sampling cohort due to 135 sampling variability.

# 136 Discussion

The provided example demonstrates the performance metrics of an algorithm and how much they can change when one does not randomly sample from the source population for algorithm validation. Oversampling of algorithm-positive cases for validation can bias model performance measures, leading to inflated sensitivity and accuracy estimates. The bias can be mitigated by considering the prevalence of disease in the source population and adjusting the calculations to account for the difference.

While sampling conditional on predicted disease status will lead to valid direct estimates 143 144 of PPV and NPV, these measures are themselves a function of disease prevalence. Thus, they 145 are not necessarily intrinsic properties of a phenotyping algorithm, and should be interpreted with caution as disease prevalence may vary across validation populations.<sup>10</sup> Likewise, 146 alternative performance measures that are in part functions of sensitivity and/or specificity, such 147 as F1-score and positive/negative likelihood ratios, will also likely be biased and require similar 148 149 corrections. Stratified study designs can also be adopted when there are covariates that may 150 correlate with differential algorithm performance, and we refer the reader to appropriate references for how to address adjustment under these conditions.<sup>6,9</sup> 151

For accurate adjustment and algorithm calibration, the source population should be defined prior to application of an algorithm. Ideally, a very high percentage of the source population will be characterized by the algorithm: if a high percentage of patients are not classified as either disease positive or negative by the algorithm, then the performance metrics of the algorithm will be difficult to interpret and this will significantly increase the difficulty of cross-institutional validation.<sup>11-13</sup>

158 This tool will enable clinicians, informaticists, and data scientists to appropriately

159 characterize performance of computable phenotype algorithms.

# 160 **References:**

Richesson RL, Smerek MM, Blake Cameron C. A Framework to Support the Sharing and Reuse of
 Computable Phenotype Definitions Across Health Care Delivery and Clinical Research Applications.
 EGEMS (Wash DC) 2016;4:1232.
 Bielinski SJ, Pathak J, Carrell DS, et al. A Robust e-Epidemiology Tool in Phenotyping Heart

Failure with Differentiation for Preserved and Reduced Ejection Fraction: the Electronic Medical Records
 and Genomics (eMERGE) Network. J Cardiovasc Transl Res 2015;8:475-83.

1673.Carroll RJ, Thompson WK, Eyler AE, et al. Portability of an algorithm to identify rheumatoid168arthritis in electronic health records. J Am Med Inform Assoc 2012;19:e162-9.

Jackson KL, Mbagwu M, Pacheco JA, et al. Performance of an electronic health record-based
 phenotype algorithm to identify community associated methicillin-resistant Staphylococcus aureus cases
 and controls for genetic association studies. BMC Infect Dis 2016;16:684.

5. Kho AN, Hayes MG, Rasmussen-Torvik L, et al. Use of diverse electronic medical record systems
to identify genetic risk for type 2 diabetes within a genome-wide association study. J Am Med Inform
Assoc 2012;19:212-8.

175 6. Gaffikin L, McGrath J, Arbyn M, Blumenthal PD. Avoiding verification bias in screening test 176 evaluation in resource poor settings: a case study from Zimbabwe. Clin Trials 2008;5:496-503.

1777.O'Sullivan JW, Banerjee A, Heneghan C, Pluddemann A. Verification bias. BMJ Evid Based Med1782018;23:54-5.

Hall MK, Kea B, Wang R. Recognising Bias in Studies of Diagnostic Tests Part 1: Patient Selection.
 Emerg Med J 2019;36:431-4.

Begg CB, Greenes RA. Assessment of diagnostic tests when disease verification is subject to
 selection bias. Biometrics 1983;39:207-15.

10. Grunau G, Linn S. Commentary: Sensitivity, Specificity, and Predictive Values: Foundations,
 Pliabilities, and Pitfalls in Research and Practice. Front Public Health 2018;6:256.

18511.Rasmussen-Torvik LJ, Furmanchuk A, Stoddard AJ, et al. The effect of number of healthcare visits186on study sample selection in electronic health record data. Int J Popul Data Sci 2020;5.

187 12. Newton KM, Peissig PL, Kho AN, et al. Validation of electronic medical record-based

phenotyping algorithms: results and lessons learned from the eMERGE network. J Am Med Inform Assoc2013;20:e147-54.

190 13. Desai JR, Wu P, Nichols GA, Lieu TA, O'Connor PJ. Diabetes and asthma case identification,

validation, and representativeness when using electronic health data to construct registries for

192 comparative effectiveness and epidemiologic research. Med Care 2012;50 Suppl:S30-5.

193

# 195 Tables

	Validation Study			Source Population		
	Chart (+)	Chart (-)	Total	Disease	No Disease	Total
Algorithm (+)	49	1	50	98	2	100
Algorithm (-)	3	47	50	60	940	1000
Total	52	48	100	158	942	1100

# **Table 1**: 2x2 contingency table definitions for phenotyping validation.

197

198

- **Table 2**: Comparison of classification performance measures based on unadjusted analysis of the
- validation study table and verification bias adjusted estimates. Note that PPV and NPV are
- 201 identical across both analyses.

Measures		Naïve	Bias-Adjusted		
Prevalence	0.520		0.091		
Accuracy	0.960		0.944		
PPV (95% CI)	0.980	[0.895,0.999]	-	-	
NPV (95% CI)	0.940	[0.838,0.979]	-	-	
Sensitivity (95% CI)	0.942	[0.844,0.980]	0.620	[0.553,0.683]	
Specificity (95% CI)	0.979	[0.891,0.999]	0.998	[0.997,0.998]	

202

## 204 Figures

# 205 Figure 1.

206

## 207 A. Mathematical definition of performance measures:

## 208 Five primary performance measures of interest:

209

$$Sensitivity = \frac{TP}{TP + FN} = \Pr(X = 1|Y = 1)$$

$$Specificity = \frac{TN}{TN + FP} = \Pr(X = 0|Y = 0)$$

$$PPV = \frac{TP}{TP + FP} = \Pr(Y = 1|X = 1)$$

$$NPV = \frac{TN}{TN + FN} = \Pr(Y = 0|X = 0)$$

$$Accuracy = \frac{TN + TP}{TN + TP + FP + FN} = \Pr(X = Y)$$

210

## 211 Additional measures of interest:



#### 213 Expected rates of TPR, TNR, FPR, and FNR in the source cohort

$TPR = PPV \times \tau^+$	$FPR = (1 - PPV) \times \tau^+$
$TP = N \times PPV \times \tau^+$	$FP = N \times (1 - PPV) \times \tau^+$
$TNR = NPV \times \tau^{-}$	$FNR = (1 - NPV) \times \tau^{-}$
$TN = N \times NPV \times \tau^{-}$	$FN = N \times (1 - NPV) \times \tau^{-}$

214

215

### 217 b) Adjusted estimates of sensitivity and specificity correcting for verification bias

$$Sensitivity^{adj} = \frac{TPR}{TPR + FNR} = \frac{PPV \times \tau^{+}}{PPV \times \tau^{+} + (1 - NPV) \times \tau^{-}}$$
$$Specificity^{adj} = \frac{TNR}{TNR + FPR} = \frac{NPV \times \tau^{-}}{NPV \times \tau^{-} + (1 - PPV) \times \tau^{+}}$$

218

#### 219

## 220 Legend

221 Consider a phenotyping algorithm for predicting the presence of a given disease condition based on a 222 patient's EHR data. We designate  $Y \in \{0,1\}$  to be the true underlying disease status for a given patient and  $X \in \{0,1\}$  to be the predicted disease status by the algorithm, such that 0 and 1 respectively denote 223 unaffected and affected disease statuses. For disease phenotyping on a patient cohort of size N, the 224 225 classification results can be summarized using a standard 2x2 contingency table, which tabulates patient 226 classifications of disease relative to true disease status into four distinct categories: true positives (TP), 227 true negatives (TN), false positives (FP), and false negatives (FN), as indicated in Table 1. Counts in the equations above can be replaced by corresponding rates by simply factoring out N (e.g., the true positive 228 rate  $TPR = \frac{TP}{N} = \Pr(Y = 1, X = 1))$ . Given that unbiased estimates of test positive and negative rates, 229  $\tau^+$  and  $\tau^-$ , are available from the algorithm classifications for the original source cohort, the expected 230 rates of TPR, TNR, FPR, and FNR in the source cohort can actually be calculated as simple functions of 231 these parameters and the PPV and NPV estimates from the validation study. For example, recall from 232 233 above that TPR can be framed as the joint probability Pr(Y = 1, X = 1). Since Pr(Y = 1, X = 1) = $Pr(Y = 1 | X = 1) \times Pr(X = 1)$  by basic rules of conditional probability, and Pr(Y = 1 | X = 1) = PPV234 and  $Pr(X = 1) = \tau^+$  per our definitions above, it follows that  $TPR = PPV \times \tau^+$ 235



Figure 2: Simulation study results demonstrating expected biases for sensitivity and specificity 237

